Biomatter has successfully raised $18 million in an oversubscribed Series A funding round led by Astanor, according to ArcticStartup. The funding was also supported by existing investors UVC Partners, Inventure, and Metaplanet. This capital infusion will help Biomatter establish a dedicated facility for enzyme design and testing in Vilnius, Lithuania, enhancing their operational capabilities.
The new facility, spanning 2,000 square meters, is aimed at streamlining the development cycle for custom enzymes. Biomatter employs artificial intelligence to design enzymes targeted for applications in areas such as biopharmaceuticals and agricultural biotechnology. This funding will enable them to expedite the design process and meet the increasing demand for custom enzyme solutions.
The planned enzyme design and testing facility is expected to significantly reduce the time from design to testing, allowing Biomatter to better serve their growing customer base.
